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TRANSLATIONAL RESEARCH

Heating Injection Drug Preparation Equipment Used for
Opioid Injection May Reduce HIV Transmission Associated
With Sharing Equipment
Laura J. Ball, MD, MPH,a Colin Venner, MSc,b Rommel G. Tirona, PhD,a Eric Arts, PhD,b
Kaveri Gupta, MD,a Joshua C. Wiener, BHSc,c Sharon Koivu, MD,d and
Michael S. Silverman, MD, FACP, FRCPa

Background: London, Canada, experienced an HIV outbreak
among persons who inject drugs despite widespread distribution of
harm reduction equipment. Hydromorphone controlled-release
(HMC) is the local opioid of choice. Injection drug preparation
equipment (IDPE; ie, cookers and ﬁlters) is often shared and reused
because of the perception that there is residual HMC in the IDPE
after use. The purpose of this study was to investigate the
mechanisms of HIV transmission in this context.

Methods:

Residual hydromorphone, (controlled-release or
immediate-release), remaining in the IDPE, was measured with
liquid chromatography–tandem mass spectrometry, in conditions
replicating persons who inject drug use. HIV was added to IDPE in
the presence HMC, hydromorphone immediate-release, or microcrystalline cellulose (an HMC drug excipient). HIV viral persistence
was measured by reverse transcriptase activity and infectivity of
indicator Tzm-bl cells.
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Results: Forty-ﬁve percent of HMC remained in the IDPE after the
ﬁrst aspiration of solution, with no change after heating. HIV
persistence and infectivity were preserved in the presence of HMC,
and less so with microcrystalline cellulose. Heating the IDPE rapidly
inactivated HIV.
Conclusions: Sharing of IDPE is a potential means of HIV
transmission. HMC encourages IDPE sharing because of the residual
drug in the IDPE, and the HMC excipients preserve HIV viability.
Heating IDPE before aspiration of the opioid may be a harm
reduction strategy.
Key Words: HIV transmission, injection drug use, prescription
opioid injection
(J Acquir Immune Deﬁc Syndr 2019;81:e127–e134)

BACKGROUND
Injection of prescription opioids has reached epidemic
levels in North America, resulting in an almost fourfold rise
in prescription opioid-related substance use disorder treatment
admissions in the United States between 2004 and 2014.1,2
This epidemic has also been associated with several large
outbreaks of HIV infection among persons who inject
prescription opioids (PWID),3–5 including one in London,
Ontario, Canada, that resulted in the declaration of a public
health emergency on June 14, 2016 (Fig. 1).6 The control of
these outbreaks generally depends on a multipronged
approach of distribution of sterile injection equipment, opioid
substitution therapy, and provision of antiretroviral therapy.7
The outbreak in London was unusual because it occurred
despite the city already having at baseline the highest
distribution of sterile needles and syringes per capita in
Canada and an opioid substitution therapy prescription rate in
the top quartile for Ontario.8 And, London has a governmentfunded, multidisciplinary HIV care program with access to
funded HIV antiretroviral therapy. The reason for this
outbreak despite the excellent pre-existing control programs
was the subject of the current investigation.
A study of injection drug users in London identiﬁed
hydromorphone controlled-release (HMC) capsules [marketed in over 15 countries on 5 continents with several brand
names, including Hydromorph Contin or Palladone SR
(Purdue Pharma, Stamford, CT) and Jurnista (Janssen-Cilag
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FIGURE 1. Count and incidence of HIV infection in Middlesex-London and Ontario, 2006–2017. The Ontario and MiddlesexLondon HIV rates (per 100,000) are shown in the red and blue lines, respectively. Middlesex-London incident HIV cases per year
are shown in the blue bars. *Denotes significantly higher (P , 0.05) incidence of HIV in Middlesex-London relative to Ontario.

Pty Ltd, Macquarie Park, New South Wales, Australia)] as the
preferred opioid for illicit use.9 Most PWID (79%) reported
HMC use in the past 6 months.9 Moreover, prescription rates
of HMC capsules were unusually high in London compared
with other regions in Ontario, which may indicate widespread
availability of the drug for diversion and injection.8
HMC capsules have a low solubility in water, and thus,
preparation of the drug for injection requires numerous steps
(Fig. 2A).10 The timed-released beads must be removed from
the capsule and crushed, mixed with water in a cooker to create
a slurry, and then drawn into a syringe through a cotton ﬁlter to
remove visible particulate matter.10 The ﬁlters, cookers, and
water are referred to as the injection drug preparation
equipment (IDPE). The high cost and large dose of hydromorphone in the controlled-release formulation, and the need
to dissolve the capsule in a large volume of water, increase the
likelihood that the IDPE will be shared between people.10 The
large volume of the solution can require multiple injections,
and therefore, PWID are tempted to divide the injections
among several people, while sharing costs. In addition, PWID
report large amounts of nonsolubilized drugs are retained in the
ﬁlter and cooker after the ﬁrst use, thereby encouraging the
reuse and sharing of used IDPE.10,11
Reuse of IDPE is achieved by adding water to the
previously used cooker containing residual drug, placing
a needle into the previously used ﬁlter, and aspirating the
residual drug (the “wash”). Multiple PWID may participate in
“serial washes,” whereby the same ﬁlter/cooker/drug complex

e128

| www.jaids.com

and needle/syringe are reused each time, with some PWID
performing and sharing as many as 7 washes from a single
preparation of HMC.10,11 While PWID reuse and share the
same IDPE, they often reuse their own, but do not share
needles/syringes (Fig. 2).
Sharing of needles/syringes among PWID has been
well established as a means of HIV transmission,12 and so
distribution of sterile needles/syringes has been a major focus
of HIV prevention programs. However, sharing of IDPE is
more common than sharing of needles/syringes.13–17 In some
centers, sharing of IDPE has been identiﬁed as the primary
risk factor for hepatitis C virus transmission,13,18–20 but its
association with HIV transmission has not been widely
studied. The incentives for sharing IDPE despite the existence
of free IDPE distribution programs have also not
been extensively studied. We recently demonstrated in
a case–control study that sharing IDPE was independently
associated with HIV infection and that negative beliefs about
heating the IDPE were also associated with HIV infection.21
We propose that in a PWID population where IDPE is
frequently shared, IDPE may become contaminated with HIV
when an HIV-positive PWID reuses their own needle to
perform another wash (including using the used needle to stir
the solution and placing the needle into the ﬁlter to aspirate
the ﬂuid) (Fig. 2B).22,23 HIV could be transmitted when the
contaminated IDPE is shared with a second, HIV-negative
PWID placing their own needle into the used ﬁlter/cooker to
aspirate another wash. We further proposed that drug

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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FIGURE 2. Method for preparing hydromorphone controlled-release for injection. A, 1. Open hydromorphone controlledrelease capsule and empty time release beads into a pill crusher to crush the beads. Empty the crushed beads into a cooker. 2.
Add approximately 1.5 mL of water to the cooker and mix using needle to stir. Allow the cooker to sit for 5 minutes at room
temperature to further dissolve the opioid. 3. Place a cotton filter into the solution. 4. Place needle in the filter and draw up the
solution into a syringe. Individuals would then inject this solution (injectate). 5. Individuals often perform multiple preparations
(washes) to extract residual drug from the filter and cooker. B, HIV may be transmitted when an HIV+ person (person 1)
performs a second wash, whereby further water is added to the residual drug in the cooker/filter and the HIV-contaminated
needle is used to stir the solution and reintroduced into the same filter; thus both the filter and residual drug in the cooker are
contaminated. Person 1 will then draw and reinject the additional injectate. The IDPE may then be shared with an HIV- person
(person 2), who would then be exposed after inserting their needle into the contaminated filter, aspirating a contaminated
injectate, and injecting it.

excipients within HMC could prolong HIV survival within
the IDPE and thus facilitating transmission; and heating the
contaminated IDPE before each use could inactivate HIV and
help prevent transmission.

METHODS
Experimental Design
The objectives of this study were to clarify the
following: (1) the amount of residual hydromorphone in
IDPE after the ﬁrst injection (and thus the incentive for IDPE
reuse) as well as the effects of heating the IDPE on the
amount of hydromorphone available for injection; and (2) the
persistence of HIV in IDPE in the presence of HMC or
a major drug excipient and the efﬁcacy of heating to
inactivate HIV to prevent transmission associated with IDPE
sharing. All experiments simulated the techniques for drug

preparation used by local PWID (Fig. 2A) and were
performed in triplicate with standard error bars displayed.

Objective 1: Residual Hydromorphone in IDPE
and Effects of Heating
All experiments were performed with unused needles/
syringes and IDPE equipment [ie, sterile water, cookers, and
ﬁlters; (Steriﬁlt; Apothicom, Paris, France)] that were distributed through the local needle exchange program as part of the
provincial harm reduction strategy and thus commonly used
by local PWID. Fluid aspirated into the syringe is referred to
as the “injectate” because it contains the ﬂuid that would be
injected by a PWID.
To quantify the amount of residual drug present in the
cooker and ﬁlter after an initial injection, we replicated the
drug preparation technique described by PWID (Fig. 2A):

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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crushing the drug, placing it in a cooker, dissolving it in
water, and aspirating the solution through a ﬁlter. We
performed this experiment with HMC capsules (24 mg;
Purdue Pharma Canada, Pickering, ON) and hydromorphone
immediate-release (HMI) tablets (8 mg; Pharmascience, Inc.,
Montreal, QC) because these are the doses and preparations
identiﬁed by local addiction counselors and patient direct
reports as those most commonly used locally by PWID. The
contents of each HMC capsule or HMI tablet were ground in
a pill crusher (Life Brand; Shoppers Drug Mart, London,
ON). The ground particles were transferred into a metal
cooker, and 2 mL of sterile water was added. Injectate
samples were obtained by drawing the resulting mixture
through a cotton ﬁlter (6 · 6-mm, tightly woven, high-density
cotton; Steriﬁlt, Slovak Republic) with a 25-G needle (BD
Canada, Mississauga, ON) into a 3-mL syringe barrel (BD
Canada). This equipment is a single unit designed to reduce
residual headspace. The effect of heating on HMC and HMI
recovery was examined by heating the preparation with
a cigarette lighter held under the cooker until the solution is
boiled (ie, bubbles formed around the edge of the cooker;
,10 seconds).
The drug residue remaining in the used ﬁlter and metal
cooker was each assayed separately and was each combined
with 3-mL methanol. Dimethylsulfoxide (SigmaAldrich, St.
Louis, MO) was added at equal volume (3 mL) to methanol,
and the resulting mixture was stored for 7 days at room
temperature to promote additional dissolution of particles.
After additional sonication (Virsonic 100; Virtis, Gardiner,
NY), the mixtures were centrifuged at 14,000g at room
temperature for 10 minutes, and the supernatants were used
for drug analysis.
Hydromorphone concentrations were measured using
liquid chromatography–tandem mass spectrometry. Standard
curve samples were prepared by diluting hydromorphone
(0–100 mg/mL ﬁnal concentration; Sigma-Aldrich) in water or
methanol/dimethylsulfoxide (50%/50%) for assays involving
injectate or ﬁlter/residue samples, respectively. Injectate
samples were diluted 500-fold with water, and an aliquot
(50 mL) was combined with internal standard, alprazolam
(10 mL, 10 mg/mL in methanol; ThermoFisher Diagnostix,
Mississauga, ON), and 50 mL of water. After centrifugation of
the sample at 14,000g at 22°C for 10 minutes, the resulting
supernatant was diluted 20-fold with 0.1% formic acid in
water. Filter/residue samples were diluted 20-fold with 0.1%
formic acid in water, and then, 50 mL was combined with
alprazolam (10 mL, 10 mg/mL in methanol) and 450 mL water.
After centrifugation, the supernatants were diluted 20-fold
with 0.1% formic acid in water.
The prepared samples were injected into the liquid
chromatograph (Agilent 1200; Agilent Technologies, San
Jose, CA), and analytes were separated using reverse phase
chromatography on a Thermo Hypersil Gold C18 column (50
· 5 mm; 5 mm) by gradient elution. The mobile phase was
delivered at a ﬂow rate of 0.5 mL/min with gradient ﬂow with
mobile phase A (0.1% formic acid in water) and mobile phase
B (0.1% formic acid in acetonitrile). For the ﬁrst 60 seconds,
the mobile phase consisted of 2% mobile phase B and then
increased linearly to 95% mobile phase B over 3 minutes.
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Thereafter, a linear decrease to 2% mobile phase B occurred
over 1 minute, which was held for an additional 1 minute. The
retention times for hydromorphone and alprazolam were 2.9
and 4.1 minutes, respectively.
Analytes were detected by tandem mass spectrometry
on a Thermo TSQ Vantage triple quadrupole instrument
(ThermoFisher, San Jose, CA) equipped with a heated
electrospray ionization probe (HESI-II) set with probe voltage
(3000 V), vaporizer temperature (400°C), ion transfer tube
temperature (350°C), sheath gas (50 arbitrary units), and
auxiliary gas (10 arbitrary units). The following multiple
reaction monitoring transitions were used with detection in
positive mode and collision gas (1.5 mTorr): hydromorphone
(286.3 / 185.2 m/z) and alprazolam (309.2 / 205.2 m/z)
with collision energy at 34 and 44 V, respectively.

Objective 2: HIV Persistence in IDPE and
Effects of Heating
HMC capsules and HMI tablets were prepared as
mentioned previously (Fig. 2A). Two controls were used
for each experiment: (1) 250 mg of the excipient microcrystalline cellulose (Sigma-Aldrich) was added to the cookers; or
(2) the cookers remained empty. HIV-1 (CXCR4 tropic
genotype #1389) at a stock titer of 1 · 108 viral particles
per mL was diluted 1:5 in sterile water (Sigma-Aldrich), and
1.5 mL was added to each cooker. This corresponds to
approximately 1–5 · 103 infectious units.27 Microcrystalline
cellulose was chosen due to its prevalence as an excipient,
including a major component of the HMC formulation.
After 5 minutes of room temperature incubation, the
solution was aspirated through the ﬁlter with a syringe (sans
needle per containment laboratory requirements). To replicate
reuse at different time points, this injectate preparation
protocol was repeated with serial washes at 1, 4, 24, 48,
and 72 hours for a total of 6 preparations for each ﬁlter. Filters
were collected after the ﬁnal aspiration. The insoluble residual
material from the HMC and microcrystalline cellulose cookers was collected after the 24-, 48-, and 72-hour time points
(50 mg per time point). To measure HIV viral persistence,
injectates were split into aliquots for HIV reverse transcriptase and infectivity assays using Tzm-bl cells. Tzm-bl cells
are highly susceptible to HIV infection and were used to
quantify viral infectivity in the injectate samples under
conditions used by PWID. Protocols for these assays have
been previously published.24 To assess the effects of heating
on HIV persistence, cookers were heated with an ethanol
ﬂame until it reached its boiling point (ie, bubbling around the
edge of the cooker, same as previous; ,10 seconds), and
Tzm-bl assays were conducted. Multiple rounds of heating
were performed to investigate the reduction in infectious
HIV particles.
All experiments with replication competent HIV-1 were
performed in a CSL2+ facility with appropriate safety and
waste protocols. HIV reverse transcriptase assays, measuring
the activity of reverse transcriptase to synthesize a radiolabeled template, were measured on a STORM 860 Phosphorimager (GE Healthcare, Chicago, IL) after 24 hours of
exposure on a phosphor screen. Tzm-bl cell assays,

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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measuring the luciferase activity produced from an HIV
responsive promoter, were measured using a Britelite Plus
luciferase kit (PerkinElmer, Waltham, MA) and read on
a Cytation 5 Plate Reader (BioTek Instruments, Winooski,
VT). All experiments were repeated with an alternate strains
of HIV-1 (R5 tropic strain #147 at stock concentrations
diluted 1:5, 1:10, and 1:20) and lower titers of X4 #1389 virus
(stocks diluted 1:10 and 1:20).

RESULTS
Objective 1: Residual Hydromorphone in IDPE
and Effects of Heating
Forty-ﬁve percent of the total hydromorphone in the
HMC capsule remained in the IDPE after the ﬁrst aspiration
and was available for use in a subsequent wash, whereas only
16% remained in the IDPE when using HMI tablets (Fig. 3).
Heating during the injection preparation did not signiﬁcantly
change the amount of hydromorphone in the solution within
the syringe after aspiration or the amount recovered from the
IDPE (Fig. 3). The preparation reached its boiling point in
less than 10 seconds when using a cigarette lighter.

Objective 2: HIV Persistence in IDPE and
Effects of Heating
Simulating drug preparation habits (Fig. 2A) with a consistent inoculum (;2–4 · 107 viral particles or ;1–5 · 103 IU27)

IDPE for Opioids and HIV Transmission

of HIV-1 added to the IDPE allowed us to quantify relative viral
persistence in different IDPE environments (Fig. 4). When
preparing the HMC for injection, infectious HIV was recovered
from the 5-minute, 1-, and 4- hour time points, which represented
3 separate washes of HIV-inoculated IDPE (Fig. 4A).
Signiﬁcantly less infectious HIV was recovered from
HIV-inoculated IDPE when preparing HMI compared with
HMC (Fig. 4A). Microcrystalline cellulose is a common ﬁller/
stabilizer in controlled-release drug formulations including
HMC and led to more HIV persistence than sterile water
control or HMI, but less than HMC (Figs. 4A, B).
In the presence of HMC, and to a lesser extent
microcrystalline cellulose, HIV reverse transcriptase activity
persisted in the IDPE and was present in the ﬂuid aspirated
into the syringe (in the injectates) despite a delay of 72 hours
after inoculation and 6 serial washes. HIV reverse transcriptase activity in the injectates was signiﬁcantly reduced in the
same conditions when originally mixed with HMI or water
(Fig. 4B). These experiments were repeated at lower infectious titers (500–2500 and 250–1250 IU) and with other
strains of HIV-1 (R5 strains #147). The R5 tropic strain of
HIV and lower titers of all HIV-1 strains only showed
detectable virus by using reverse transcriptase at the 5-minute
and 1-hour time points (see Figure 1, Supplemental Digital
Content, http://links.lww.com/QAI/B316). All future time
points in these experiments were negative. Lower concentrations of X4-tropic HIV #1389 were also negative after the
5-minute time point.

FIGURE 3. Relative amount of hydromorphone recovered in the syringe (injectate sample) and injection drug preparation
equipment [filter and residue (left in cooker)] with and without heating. A, Hydromorphone controlled-release 24 mg and (B)
hydromorphone immediate-release 8 mg; doses used were those most commonly injected locally. After preparation of the drug
mixtures using the technique commonly used by persons who inject drugs, hydromorphone concentrations were measured using
liquid chromatography–tandem mass spectrometry. Error bars represent the standard error.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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FIGURE 4. HIV infectivity and persistence after addition to injection drug preparation equipment. A, Infectivity of HIV-1 in injectates
was determined by Tzm-bl cell luciferase production. HIV-1 was inoculated into cookers containing hydromorphone controlledrelease or immediate-release, microcrystalline cellulose, or empty cookers to measure viral persistence. Serial washes with sterile
water were collected 5 minutes, 1, and 4 hours after addition of virus. Maximal preservation of infectivity over time was seen with
hydromorphone controlled-release across all measured time points. B, HIV-1 was added into cookers with varying opioid or drug
excipient preparations to measure viral HIV-1 in the injectate solution. HIV-1 reverse transcriptase activity was assessed after 72 hours
in the injectate solution (after 6 serial washes of the IDPE). Hydromorphone controlled-release and microcrystalline cellulose showed
the greatest reverse transcriptase activity at 72 hours. C, The same method as (B) was used to measure viral HIV-1 in the filter after 72
hours. In the presence of hydromorphone controlled-release, HIV-1 reverse transcriptase activity is significantly greater than hydromorphone immediate-release. It is below the level of detection in the presence of microcrystalline cellulose and water. Dashed
lines represent assay detection limits. Error bars represent the standard error. *Significant at P , 0.05, **Significant at P , 0.01 by 2way ANOVA with the Tukey correction for multiple comparisons. ANOVA, analysis of variance.

There were some visible differences between pure
microcrystalline cellulose and the excipients inside the HMC
capsule. HMC, when emptied, resembles small beads that have
a foam-like resistance compared with the powdered pure
cellulose. These differences, and potentially the other ingredients in HMC, seem to allow for the ﬁlter to retain HIV when
impregnated with HMC. Microcrystalline cellulose retains HIV
in the drug residue itself but does not impregnate the ﬁlter and
thus, on its own, may not result in persistence of infectious
HIV. To explore these differences further, we attempted, but
failed, to obtain the complete formulation of the HMC capsule
without the active opioid from Purdue Pharmaceuticals.
To identify whether HIV was retained in the ﬁlters
(where the needle tip of a second user would be placed), we
measured reverse transcriptase activity in the ﬁlters remaining
in the cooker after 72 hours. Higher levels of reverse
transcriptase activity (ie, HIV) were observed in the ﬁlters
in the presence of HMC compared with the other compounds
(Fig. 4C). Heating the cookers with the HMC solution to
a boil reduced the residual infectious HIV-1 titers in the
injectate by 2 logs but did not eliminate infectious HIV. A
second round of heating to a boil reduced the HIV-1 titers to
the limits of detection (dotted line represents the virus-free
control, Fig. 5). Further rounds of heating were performed but
demonstrated no further reduction in the infectious HIV titer.

DISCUSSION

These results provide the ﬁrst evidence that 45% of the
contents from an HMC capsule remain in the IDPE after an
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initial use, thereby incentivizing the behavior of frequent
IDPE reuse to access retained HMC. The current local street
value of a capsule of HMC is approximately $60 CAD ($45
USD), and therefore, disposal of the remaining drug in the
IDPE (a $27 CAD value) is very uncommon. This leads to
IDPE being commonly shared and sold among PWIDs,
despite nearly absent sharing of needles and syringes.10 By
contrast, the low quantity of residual HMI on the IDPE,
because of the lower dose and higher solubility of immediaterelease opioids, provides less incentive to reuse the IDPE.
These ﬁndings likely explain the common behavior of
multiple repeated uses of IDPE and the sharing of washes
with HMC but not HMI.10,21
We demonstrated prolonged HIV survival in IDPE used
in the preparation of controlled-release opioid (up to 3 days)
compared with that used for an immediate-release opioid
preparation. Although it has been demonstrated that HIV
RNA can be found in high titer in IDPE used by PWID, the
speciﬁc drugs used and their relative abilities to preserve HIV
were not described in these studies.22,23 It has been shown
that HIV survival is reduced in the presence of heroin, but it is
unclear whether this was related to the heating process
required for home production or the many caustic chemicals
added to produce the solution.25 To the best of our
knowledge, this study is the ﬁrst to assess HIV persistence
in the presence of prescribed opioids that do not require
heating or the addition of extra chemicals for solubility.
Because PWID commonly reinsert their own used
needle into the IDPE from multiple washes using a single
needle/syringe,10 this can lead to the IDPE becoming

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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FIGURE 5. Reduction in infectious HIV-1 (measured by Tzm-bl
cell luciferase production) after ,10 seconds heat treatment.
HIV-1 was added to cookers containing 24 mg of hydromorphone controlled-release and a cotton filter and washed
with sterile water. Serial washes 1 and 2 were collected 5 minutes and 1 hour after HIV-1 addition, respectively. Cookers
were then heated above a flame for ,10 seconds (until bubbling) or left at room temperature during each wash. Persisting infectious HIV-1 in the injectate (fluid aspirated into a
syringe for injection) was quantified by luciferase production
from Tzm-bl cells. Dashed line represents the assay’s detection
limit. Error bars represent the standard error. **Significant at
P , 0.001 by using 2-tailed t test.

contaminated with HIV. When a second PWID inserts their
needle into the same ﬁlter, they can become infected through
injecting. Although most PWID are careful not to share
needles/syringes, they commonly reuse their own needles/
syringes because they are unaware that it may contaminate the
IDPE and thus increase the risk of HIV transmission through
this mechanism.11 Our demonstration that HIV can be
detected not only in the injectate aspirated into the syringe
from the used IDPE but also in the ﬁlter into which the second
needle would be inserted suggests that contamination of the
second PWID’s injection would be very feasible (Figs. 2B
and 4).
HIV persistence may be related to excipients in the
controlled-release preparation because persistence was not
seen with HMI tablets. Speciﬁcally, excipients in HMC that
are not in HMI include ethyl cellulose, hydroxypropyl
methylcellulose, and microcrystalline cellulose.26 Addition
of microcrystalline cellulose alone to the IDPE retained more
viable HIV and for longer than IDPE when used with water or
with HMI. Cellulose-containing drugs may maintain hydra-

IDPE for Opioids and HIV Transmission

tion, resulting in virus preservation. In fact, methylcellulose
derivatives are a major constituent in media to maintain
hydration and limit diffusion for viral plaque assays used for
clinical diagnostics.26 For pharmaceuticals with this agent
that may be diverted for injection (eg, opioids), industry
should consider seeking alternative excipients given the
potential increased risk of bloodborne pathogen transmission.
The limiting sensitivity of the Tzm-bl assay prevented
us from measuring infectivity beyond 4 hours (ie, third wash).
However, previous research has indicated that reverse
transcriptase activity in HIV-1 is a strong predictor of virus
infectivity and has greater sensitivity/speciﬁcity than other
surrogate assays such as p24 ELISAs or viral RNA load.27
We demonstrated that heating IDPE until boiling
(“cooking the wash”) reduced the amount of virus in the
injectate to the limit of detection after 2 rounds of heating
(Fig. 5). This process was found to be very easily performed,
with boiling of the HMC solution occurring in less than 10
seconds when using a cigarette lighter; this demonstrated
feasibility for widespread use by PWID and is locally referred
to as “cooking your wash”. The campaign emphasized the
importance of cooking each wash to get the viral and
bacterial28 reduction beneﬁts of serial boiling. Cooking the
wash did not signiﬁcantly increase the amount of hydromorphone in the injectate, and thus, should not lead to
accidental overdose. And, it did not signiﬁcantly reduce the
amount of drug obtained, and so PWID should ﬁnd it to be an
acceptable harm reduction technique.
Using a sterile (ie, previously unused) needle for every
aspirate of a drug is another useful strategy in preventing viral
contamination of IDPE, but this alone will not reduce the risk
of bacterial contamination of the injectate from repeated
handling; boiling is necessary to reduce this potential
bacterial load.28 Boiling until there are bubbles present (for
,10 seconds) as performed in this study did markedly reduce
the burden of bacterial contamination,28 in another recent
study which we reported, and so this degree of boiling was
used in this study and in the public health campaign to have
a comprehensive intervention that could reduce both bacterial
and viral risks. In vitro studies using alternative boiling
durations and other pathogens may be helpful to optimize this
intervention. Cleaning the IDPE with bleach before reuse has
been occasionally recommended as another strategy, although
it would not be acceptable in the context of retained drug and
injectate being exposed to the caustic effects of bleach. Given
that the formulation of HMC is a speciﬁc risk factor for reuse,
the provision of injectable hydromorphone should also be
considered, as per the SALOME trials.29
Based on the results of the current study, a “cook your
wash” public education campaign was initiated in June 2017.
The campaign recommended PWID to heat their IDPE with
a cigarette lighter until bubbling for each wash before
aspiration. Preliminary data showed a decrease in new HIV
diagnoses in the second half of 2017, such that the HIV
incidence for 2017 was no longer signiﬁcantly above the
provincial rate (Fig. 1). Anecdotal evidence suggests widespread uptake of the recommendation by PWID, but further
studies are ongoing to document the changes in behavior
associated with the campaign.
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A limitation of this study is that we were unable to get
access to used IDPE that would be suitable for testing for
replication competent virus. This was because there was a strong
effort to place all HIV patients on antiretrovirals immediately
after diagnosis as per recent recommendations. Therefore, we
did not have access to IDPE, which had been used by patients
with high plasma viral loads. This meant that it was very
unlikely that we would detect replication competent virus in the
IDPE as this would have been difﬁcult to do even with plasma.
The recent outbreaks of HIV in PWID emphasize the need
for understanding all mechanisms of transmission. London had
an outbreak of HIV despite having excellent pre-existing
traditional HIV prevention programs for PWID. The outbreak
was facilitated by the dual effect of a controlled-release opioid,
which not only increases HIV survival in IDPE but also provides
an incentive for sharing IDPE because of drug retention. These 2
effects seem to be synergistic in facilitating HIV transmission.
Preventing IDPE sharing will be difﬁcult due to the retention of
valued drug in the IDPE after use, but promoting the heating of
IDPE before each use may be an effective approach to reduce
HIV infection. As the popularity of injecting prescription opioids
continues to increase,2,10 the implementation of harm reduction
strategies that target IDPE sharing as a mechanism of HIV
transmission will become increasingly important.
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